Moleculin Biotech's Annamycin Trial Shows Positive Interim Results for AML

Moleculin Biotech announced positive preliminary blinded interim data from Part A of its Phase 2/3 MIRACLE trial for Annamycin combined with cytarabine (AnnAraC) in relapsed/refractory acute myeloid leukemia (R/R AML). The trial reported a 24% complete remission (CR) rate and a 37% composite complete remission (CRc) rate after one cycle in 62 subjects. Notably, patients who previously failed venetoclax-based regimens showed a 37% CRc rate, indicating potential for a new therapy in a difficult-to-treat subgroup.